Post by
retiredcf on Mar 19, 2021 8:14am
Canaccord Upgrade
Separately, following its US$158-million acquisition of Massachusetts-based Cultivate, Mr. Dley (Canaccord) raised his target for Cresco Labs Inc. (CL-CN) to $22 from $20.50, keeping a “speculative buy” rating. The average on the Street is $22.22.
“In our view, Cresco is well positioned to capitalize on the increasing acceptance of cannabis within its core states, boasts a best-in-class management team, and offers investors a differentiated cannabis opportunity through its focus on both wholesale and retail,” he said.
Be the first to comment on this post